Abstract
A new randomized clinical trial shows that tocilizumab, a monoclonal antibody that inhibits IL-6 signalling by binding to the IL-6 receptor, increases myocardial salvage in patients with acute ST-segment elevation myocardial infarction who undergo myocardial revascularization with percutaneous coronary intervention.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
